Cytosorbents Corporation
CTSO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $9,485 | $9,617 | $8,727 | $9,150 |
| % Growth | -1.4% | 10.2% | -4.6% | – |
| Cost of Goods Sold | $2,819 | $2,803 | $2,520 | -$248 |
| Gross Profit | $6,666 | $6,814 | $6,208 | $9,398 |
| % Margin | 70.3% | 70.9% | 71.1% | 102.7% |
| R&D Expenses | $918 | $1,262 | $1,663 | $1,297 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $8,610 | $0 | $0 | $9,519 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $9,167 | $8,432 | $2,627 |
| Operating Expenses | $9,528 | $10,429 | $10,095 | $13,444 |
| Operating Income | -$2,862 | -$3,615 | -$3,887 | -$4,045 |
| % Margin | -30.2% | -37.6% | -44.5% | -44.2% |
| Other Income/Exp. Net | -$709 | $5,562 | $2,409 | -$5,529 |
| Pre-Tax Income | -$3,571 | $1,947 | -$1,478 | -$9,575 |
| Tax Expense | -$401 | $0 | $0 | -$1,691 |
| Net Income | -$3,170 | $1,947 | -$1,478 | -$7,884 |
| % Margin | -33.4% | 20.2% | -16.9% | -86.2% |
| EPS | -0.05 | 0.031 | -0.024 | -0.14 |
| % Growth | -260.8% | 228% | 82.6% | – |
| EPS Diluted | -0.05 | 0.029 | -0.024 | -0.14 |
| Weighted Avg Shares Out | 62,754 | 62,609 | 60,732 | 54,715 |
| Weighted Avg Shares Out Dil | 62,754 | 67,166 | 60,732 | 54,715 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $645 | $616 | $605 | $624 |
| Depreciation & Amortization | $0 | $404 | $369 | $426 |
| EBITDA | -$2,926 | -$3,211 | -$3,519 | -$8,525 |
| % Margin | -30.8% | -33.4% | -40.3% | -93.2% |